AstraZeneca Pharma India Limited announced the resignation of two senior management personnel, Mr. Ayush Kumar Agarwal and Ms. Shikha Mirchandani Chatrath, who are leaving to pursue career opportunities outside the organization. The company disclosed that it is currently searching for suitable replacements to fill the vacant leadership positions. The resignations were intimated to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Ayush Kumar Agarwal served as the Business Unit Director – Biopharmaceutical Business Unit. He will complete his handover period and be relieved from his duties by the close of business hours on June 12, 2026. Ms. Shikha Mirchandani Chatrath held the position of Director – Commercial Excellence, BD and Strategy. She is scheduled to complete her handover and exit the company by the close of business hours on August 3, 2026.

The details of the resignations were provided in accordance with SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirmed that the term of appointment and brief profiles for the positions were not applicable as per the submitted annexure. The company thanked the executives for their contributions and wished them success in their future endeavours.

Resignation Details

AstraZeneca Pharma India Limited reported a 33% year-on-year growth in total revenue from operations to ₹22,755.80 Mn for the financial year ended March 31, 2026. The company's Board of Directors recommended a dividend of ₹36 per equity share for the financial year, subject to shareholder approval. Additionally, the Board approved the re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director and the appointment of M/s. BSR & Co. LLP as Statutory Auditors.

The audited financial results were approved at the Board meeting held on May 26, 2026. The Statutory Auditor's Report carries an unmodified opinion.

Financial Performance

The company's full-year and quarterly financial highlights are presented below:

While full-year revenue and profitability showed strong growth, Q4 results reflected a year-on-year decline across key profitability metrics. Net profit for Q4 fell to ₹448.80 Mn from ₹582.50 Mn in the prior-year quarter, even as quarterly revenue grew to ₹5,786.10 Mn from ₹4,804.80 Mn year-on-year.

Therapy Area-wise Revenue (FY26)

Oncology remained the primary growth driver for the full year, followed by Biopharmaceuticals and Rare Disease, as detailed below:

Key Regulatory Approvals in FY26

The company received 11 regulatory approvals during the year, supported by strong momentum across its therapy areas. Key milestones include:

• Durvalumab – Endometrial Cancer: CDSCO approval for two additional indications, including first-line treatment in combination with carboplatin and paclitaxel, followed by maintenance with Olaparib in pMMR endometrial cancer.
• Durvalumab – Muscle Invasive Bladder Cancer (MIBC): CDSCO approval as adjuvant treatment following radical cystectomy for adult patients with MIBC.
• Eculizumab – Rare Diseases: Launched as the first anti-complement therapy approved in India for atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
• Osimertinib – NSCLC: Approval for combination use with pemetrexed and platinum-based chemotherapy for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.
• Osimertinib – Stage III NSCLC (Monotherapy): CDSCO approval as monotherapy for locally advanced, unresectable (stage III) NSCLC following platinum-based chemoradiation therapy.
• Trastuzumab Deruxtecan – HER2 Spectrum Expansion: Approval for HER2-low and HER2-ultralow metastatic breast cancer patients who have received at least one endocrine therapy in the metastatic setting.
• Benralizumab – EGPA: Approval as add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis.
• Sodium Zirconium Cyclosilicate (5g/10g) – Hyperkalaemia: CDSCO permission for import and sale for management of hyperkalaemia in adults, in partnership with Sun Pharma.
• Durvalumab – Gastric Cancer: Approval in combination with FLOT chemotherapy as perioperative treatment for resectable gastric or gastroesophageal junction adenocarcinoma, based on the MATTERHORN trial.
• Durvalumab – Liver Cancer: Expanded approval for Durvalumab plus tremelimumab for first-line treatment of unresectable hepatocellular carcinoma, following the HIMALAYA trial results.

Management Commentary

Bhavana Agrawal, Chief Financial Officer & Director, said: "FY 2025-26 was a year of strong and consistent growth for AstraZeneca India, underpinned by the resilience of our business, the strength of our science-led portfolio, and disciplined execution across the organisation. Our performance reflects not only commercial momentum, but also our continued commitment to creating sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet."

Praveen Rao Akkinepally, Managing Director, added: "At AstraZeneca, science is at the heart of everything we do. Our FY 2025-26 performance reflects the progress we are making, accelerating the delivery of innovative medicines across key therapy areas and advancing our ambition to transform patient outcomes in India. With a strong pipeline and a clear sense of purpose, we remain focused on addressing unmet medical needs, advancing the healthcare ecosystem, and creating long-term impact through science-led innovation."